NCT07062536View on ClinicalTrials.gov

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2028

Conditions
Biliary Cancer Metastatic
Interventions
DRUG

Oxaliplatin, 5FU, leucovorin

Administered as a single regimen every 2weeks

DRUG

Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,

Administered alternately every 2weeks

Trial Locations (1)

13605

Jin Won Kim, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER